Want to see LKFT full AI Analyst Report?

Lakefront Biotherapeutics (LKFT) Price & Analysis

549 Followers

LKFT Stock Chart & Stats

$29.16

-$0.67(-2.33%)

At close: Jan 08 4:00 PM EST

$29.16

-$0.67(-2.33%)

Day’s Range― - ―

52-Week Range$25.68 - $37.78

Previous CloseN/A

VolumeN/A

Average Volume (3M)285.33K

Market Cap

$1.94B

Enterprise Value-$451.30

Total Cash (Recent Filing)$2.24B

Total Debt (Recent Filing)$6.36M

Price to Earnings (P/E)2.9

Beta0.65

Next Earnings

Nov 12, 2026

EPS Estimate

-0.83

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)9.05

Shares Outstanding65,897,070

10 Day Avg. Volume442,202

30 Day Avg. Volume285,331

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.57

Price to Sales (P/S)1.65

P/FCF Ratio-6.76

Enterprise Value/Market Cap>-0.01

Enterprise Value/Revenue>-0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$35.50

Price Target Upside21.74% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-2.94

Revenue Forecast (FY)$32.33M

Bulls Say, Bears Say

Bulls Say

Very Strong Balance SheetMinimal leverage and a large equity base provide substantial financial flexibility for a biotechnology company pursuing clinical development and strategic transactions. This balance-sheet strength can help fund operations, absorb setbacks, and preserve options without relying heavily on external financing.

Strong Current ProfitabilityStrong TTM gross, operating, and net margins indicate that the company currently converts reported revenue into meaningful accounting profit. Improving net income supports internal funding capacity and gives management more resources to advance its portfolio, although consistency remains important.

Deep Liquidity And Portfolio ExpansionReaffirmed cash guidance and at least €1.6 billion of expected remaining cash provide a substantial runway for strategic transactions and development through potential gamgertamig approval. Adding autoimmune and inflammatory programs also broadens the future pipeline around immunology.

Bears Say

Persistent Cash BurnNegative operating and free cash flow despite reported profits raises questions about earnings conversion and the durability of internal cash generation. Continued cash consumption increases execution risk and makes future investment plans more dependent on the existing balance sheet.

Revenue VolatilityThe reversal from strong annual revenue growth to a TTM decline indicates that the current revenue base may be uneven rather than steadily compounding. Lower collaboration revenue can reduce operating visibility and make future profitability more dependent on portfolio progress.

Inconsistent Profitability QualityPast operating losses, negative net income, and inconsistent returns weaken confidence that the latest strong profitability will persist across development and portfolio transitions. This history makes execution and repeatability important risks even with current margins and liquidity.

Lakefront Biotherapeutics News

Microsoft upgraded, HubSpot initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

8d ago

ALV

ARX

Lakefront upgraded to Outperform from Sector Perform at RBC Capital

RBC Capital upgraded Lakefront Biotherapeutics (LKFT) to Outperform from Sector Perform with a price target of $45, up...

8d ago

LKFT

Lakefront Biotherapeutics granted orphan drug designation for gamgertamig

Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of...

1M ago

GILD

LKFT

Lakefront Biotherapeutics Buys Back 104K Shares in August Repurchase Tranche

An announcement from Lakefront Biotherapeutics ( ($LKFT) ) is now available. Between August 3 and August 7, 2026,...

2M ago

LKFT

Lakefront Biotherapeutics Posts First-Half 2026 Results, Closes Ouro Deal and Reaffirms €2B Cash Guidance

Lakefront Biotherapeutics ( ($LKFT) ) just unveiled an update. On August 10, 2026, Lakefront Biotherapeutics reported unaudited first-half...

2M ago

LKFT

Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley

Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Lakefront Biotherapeutics (LKFT) to $26 from $30...

2M ago

LKFT

Is LKFT a Buy, Before Earnings?

Lakefront Biotherapeutics (LKFT) is scheduled to report 2nd quarter earnings on 08/10/2026. Regarding Q2 estimates, Wall Street analysts...

2M ago

LKFT

Lakefront Biotherapeutics Buys Back 98,648 Shares Under Ongoing Repurchase Program

The latest announcement is out from Lakefront Biotherapeutics ( ($LKFT) ). On July 21, 2026, Lakefront Biotherapeutics reported...

2M ago

LKFT

Lakefront Biotherapeutics Board Member Resigns After Sanofi R&D Appointment

Lakefront Biotherapeutics ( ($LKFT) ) has provided an update. Lakefront Biotherapeutics, a Belgium-based biotechnology company listed on Euronext...

3M ago

LKFT

Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley

Morgan Stanley resumed coverage of Lakefront Biotherapeutics (LKFT) with an Equal Weight rating and $30 price target after...

3M ago

GILD

LKFT

Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside

Morgan Stanley analyst Judah Frommer maintained a Hold rating on Lakefront Biotherapeutics today and set a price target...

3M ago

LKFT

Lakefront Biotherapeutics Buys Back Over 104,000 Shares Under June 2026 Repurchase Program

Lakefront Biotherapeutics ( ($LKFT) ) has provided an update. Between June 29 and July 3, 2026, Lakefront Biotherapeutics...

3M ago

LKFT

Lakefront Biotherapeutics Details June Share Buybacks Under Ongoing Repurchase Program

Lakefront Biotherapeutics ( ($LKFT) ) has shared an announcement. Between June 22 and June 26, 2026, Lakefront Biotherapeutics...

3M ago

LKFT

Lakefront Biotherapeutics Discloses New 5% Stake by Madison Avenue Partners

Lakefront Biotherapeutics ( ($LKFT) ) has issued an update. On June 29, 2026, Lakefront Biotherapeutics reported that it...

3M ago

LKFT

LKFT FAQ

What was Lakefront Biotherapeutics’s price range in the past 12 months?

Lakefront Biotherapeutics lowest stock price was $25.68 and its highest was $37.78 in the past 12 months.

What is Lakefront Biotherapeutics’s market cap?

Lakefront Biotherapeutics’s market cap is $1.94B.

When is Lakefront Biotherapeutics’s upcoming earnings report date?

Lakefront Biotherapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 42 days.

How were Lakefront Biotherapeutics’s earnings last quarter?

Lakefront Biotherapeutics released its earnings results on Aug 10, 2026. The company reported $0.034 earnings per share for the quarter, beating the consensus estimate of -$0.823 by $0.857.

Is Lakefront Biotherapeutics overvalued?

According to Wall Street analysts Lakefront Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lakefront Biotherapeutics pay dividends?

Lakefront Biotherapeutics does not currently pay dividends.

What is Lakefront Biotherapeutics’s EPS estimate?

Lakefront Biotherapeutics’s EPS estimate is -0.83.

How many shares outstanding does Lakefront Biotherapeutics have?

Lakefront Biotherapeutics has 65,897,070 shares outstanding.

What happened to Lakefront Biotherapeutics’s price movement after its last earnings report?

Lakefront Biotherapeutics reported an EPS of $0.034 in its last earnings report, beating expectations of -$0.823. Following the earnings report the stock price went up 6.763%.

Which hedge fund is a major shareholder of Lakefront Biotherapeutics?

Currently, no hedge funds are holding shares in LKFT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Lakefront Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-14.52%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Lakefront Biotherapeutics

Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.

Lakefront Biotherapeutics (LKFT) Earnings & Revenues

Historic Earnings Reports

LKFT Company Deck

LKFT Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights a major strategic transformation with a high‑profile Ouro/Gilead transaction that brings a promising clinical asset (gamgertamig) and unlocks substantial financial flexibility. Operationally, the company reported meaningful quarterly improvement in operating loss and a net profit driven by financial gains, maintained a strong cash position, and emphasized cost discipline and capital‑efficient development plans. Offsetting these positives are a very large near‑term cash deployment (upfront and wind‑down costs), a steep YoY revenue decline driven by prior‑year accounting recognition, continued operating losses, and clinical and competitive risks inherent to the BCMA/CD3 space. On balance, the strategic upside and improved reported results outweigh the near‑term financial outflows and risks.View all LKFT earnings summaries

LKFT Stock 12 Month Forecast

Average Price Target

$35.50

▲(21.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","46":"$46","30.25":"$30.3","35.5":"$35.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,30.25,35.5,40.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.55,29.815384615384616,31.08076923076923,32.34615384615385,33.61153846153846,34.87692307692308,36.142307692307696,37.40769230769231,38.67307692307692,39.93846153846154,41.20384615384616,42.46923076923077,43.73461538461538,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.55,29.084615384615386,29.61923076923077,30.153846153846153,30.68846153846154,31.223076923076924,31.75769230769231,32.292307692307695,32.82692307692308,33.36153846153846,33.896153846153844,34.43076923076923,34.965384615384615,{"y":35.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.55,28.353846153846156,28.157692307692308,27.961538461538463,27.765384615384615,27.56923076923077,27.373076923076923,27.176923076923078,26.98076923076923,26.784615384615385,26.588461538461537,26.392307692307693,26.196153846153848,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.16,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":35.04,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.78,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.13,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.7,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":34.23,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":34.09,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.54,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.21,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":28.55,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >